Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Clinical overview of the seizure risk of dalfampridine.
Laquinimod
Natural History of Multiple Sclerosis Symptoms
T cells become licensed in the lung to enter the central nervous system.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Daclizumab (anti-CD25) in multiple sclerosis.
Genzyme's Lemtrada resubmission accepted for review by FDA
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Biomarkers for Brain Disorders: Challenges and Opportunities

Pages